MedPath

NAPP PHARMACEUTICALS LIMITED

🇬🇧United Kingdom
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:2

Trial Phases

1 Phases

Phase 4:2

Drug Approvals

113

NMPA:68
EMC:42
SFDA:3

Drug Approvals

Morphine Sulphate Sustained-release Tablets

Product Name
硫酸吗啡缓释片
Approval Number
国药准字HJ20130904
Approval Date
Aug 6, 2024
NMPA

Morphine Sulphate Sustained-release Tablets

Product Name
硫酸吗啡缓释片
Approval Number
国药准字HJ20130903
Approval Date
Aug 6, 2024
NMPA

Morphine Sulphate Sustained-release Tablets

Product Name
硫酸吗啡缓释片
Approval Number
国药准字HJ20130901
Approval Date
Jun 14, 2024
NMPA

Morphine Sulphate Sustained-release Tablets

Product Name
硫酸吗啡缓释片
Approval Number
国药准字HJ20130900
Approval Date
Jun 14, 2024
NMPA

Oxycodone Hydrochloride Prolonged-release Tablets

Product Name
奥施康定
Approval Number
国药准字HJ20140324
Approval Date
Feb 6, 2024
NMPA

Oxycodone Hydrochloride Prolonged-release Tablets

Product Name
奥施康定
Approval Number
国药准字HJ20170052
Approval Date
Feb 6, 2024
NMPA

Oxycodone Hydrochloride Prolonged-release Tablets

Product Name
奥施康定
Approval Number
国药准字HJ20140314
Approval Date
Feb 6, 2024
NMPA

Oxycodone Hydrochloride Prolonged-release Tablets

Product Name
奥施康定
Approval Number
国药准字HJ20140320
Approval Date
Feb 6, 2024
NMPA

Oxycodone Hydrochloride Prolonged-release Tablets

Product Name
奥施康定
Approval Number
国药准字HJ20140312
Approval Date
Feb 6, 2024
NMPA

Oxycodone Hydrochloride Prolonged-release Tablets

Product Name
奥施康定
Approval Number
国药准字HJ20140313
Approval Date
Feb 6, 2024
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 4
2 (100.0%)

A Study to Compare Oxycodone/Naloxone Prolonged Release Against Codeine/Paracetamol in the Treatment of Moderate to Severe Chronic Low Back Pain or Pain Due to Osteoarthritis

Phase 4
Completed
Conditions
Osteoarthritis
Back Pain
Interventions
Drug: Oxycodone/Naloxone
Drug: Codeine/Paracetamol
First Posted Date
2008-11-04
Last Posted Date
2011-11-02
Lead Sponsor
Napp Pharmaceuticals Limited
Target Recruit Count
247
Registration Number
NCT00784810

Buprenorphine in the Treatment of Osteoarthritis (OA) in the Elderly

Phase 4
Completed
Conditions
Osteoarthritis
Interventions
First Posted Date
2006-05-10
Last Posted Date
2011-06-14
Lead Sponsor
Napp Pharmaceuticals Limited
Target Recruit Count
219
Registration Number
NCT00324038
Locations
🇬🇧

Napp Pharmaceuticals Ltd, Cambridge, United Kingdom

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.